REGULATORY INTELLIGENCE·Warning Letter
FDA Intensifies Scrutiny on Amgen's Tavneos as Pivotal Study Data Retracted
Amgen faces significant regulatory and commercial challenges as a leading medical journal retracts pivotal study data for its rare disease medicine, Tavneos. This intensifies FDA pressure, jeopardizing market access and physician confidence. Procurement and regulatory teams must assess supply stability and Amgen's broader compliance posture, given its history of regulatory scrutiny.
90-Day Activity